ArticleF1000Research2017
Abnormal expression of
Article in F1000Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- YAP-mediated mechanotransduction promotes hepatocellular carcinoma progression by targeting ATP1A1/CXCL1 axis.Acta pharmacologica Sinica · 2026Article
- Identification and prognostic analysis of genes related to CTNNB1 mutations in hepatocellular carcinoma.Biology direct · 2026Article
- Comparative analysis and correlation of cancer hotspot proteins and cell markers in tumor-normal adjacent breast and kidney samples using RPPA and LC-MS.Scientific reports · 2026Article
- LAPTM4B Confers Resistance to EGFR-TKIs by Suppressing the Proteasomal Degradation of ATP1A1 in Non-small Cell Lung Cancer.International journal of biological sciences · 2026Article
- Inhibition of NaBiomedical engineering online · 2025Article
- Integrating network pharmacology and transcriptomics to identify solasonine's anti-osteosarcoma targets and experimental validation.Frontiers in oncology · 2025Article
- The natural compound periplogenin suppresses the growth of prostate carcinoma cells by directly targeting ATP1A1.Scientific reports · 2024Article
- Hypomethylation of ATP1A1 Is Associated with Poor Prognosis and Cancer Progression in Triple-Negative Breast Cancer.Cancers · 2024Article
- ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy.Cancer cell international · 2024Article
- Identification of Novel Prognostic Biomarkers That are Associated with Immune Microenvironment Based on GABA-Related Molecular Subtypes in Gastric Cancer.Pharmacogenomics and personalized medicine · 2023Article
- Homophilic ATP1A1 binding induces activin A secretion to promote EMT of tumor cells and myofibroblast activation.Nature communications · 2022Article
- Identification of ITPR1 as a Hub Gene of Group 3 Medulloblastoma and Coregulated Genes with Potential Prognostic Values.Journal of molecular neuroscience : MN · 2022Article
- Identification of Potential Biomarkers for Progression and Prognosis of Bladder Cancer by Comprehensive Bioinformatics Analysis.Journal of oncology · 2022Article
- Clinical significance of P-class pumps in cancer.Oncology letters · 2021Review
- IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion.Oncogene · 2020Article
- RNA-seq analysis identified hormone-related genes associated with prognosis of triple negative breast cancer.Journal of biomedical research · 2020Article
- DNLC: differential network local consistency analysis.BMC bioinformatics · 2019Article
- Article
- OMICfpp: a fuzzy approach for paired RNA-Seq counts.BMC genomics · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the first in incidence and the second in death among all solid tumors occurring in women. The identification of molecular genetic abnormalities in breast cancer is important to improve the results of treatment. In the present study, we analyzed microarray data of breast cancer expression profiling (NCBI GEO database, accession GSE65194), focusing on Na
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.